|
Status |
Public on Aug 07, 2024 |
Title |
LAG3 and PD1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN gamma-dependent anti-tumor immunity |
Organism |
Mus musculus |
Experiment type |
Expression profiling by high throughput sequencing Other
|
Summary |
Combined nivolumab (anti-PD1) and relatlimab (anti-LAG3) have shown enhanced effectiveness in melanoma patients. However, how these two receptors work together to hinder anti-tumor immunity remains unclear. Our study demonstrates that PD1/LAG3-deficient CD8+ T cells with more effectively clearing tumors and survive longer in melanoma mouse models. These PD1/LAG3-deficient CD8+ T cells have unique transcriptional profiles, broad TCR clonality, and enriched effector-like and interferon-responsive genes, leading to increased IFN gamma release indicating functionality. PD1 and LAG3 together drive T cell exhaustion, with a significant impact on TOX modulation. Mechanistically, autocrine IFN gamma signaling is crucial for enhancing anti-tumor immunity in PD1/LAG3-deficient CD8+ T cells, providing insights into the enhanced efficacy of combined PD1 and LAG3 targeting.
|
|
|
Overall design |
We employed single-cell RNA sequencing to profile CD8 cells from polyclonal/pMEL mice, both with and without single or double deficiencies of PD1 or LAG3. This comprehensive approach aimed to gain a deeper understanding of the enhanced efficacy observed in the melanoma model.
|
Web link |
https://www.cell.com/cell/abstract/S0092-8674(24)00776-1
|
|
|
Contributor(s) |
Andrews LP, Cui J, Vignali DA |
Citation(s) |
39121848 |
|
Submission date |
Mar 28, 2024 |
Last update date |
Aug 10, 2024 |
Contact name |
Jian Cui |
E-mail(s) |
cuij@pitt.edu
|
Organization name |
University of Pittsburgh
|
Department |
Immunology
|
Lab |
Vignali Lab
|
Street address |
5051 Centre Avenue
|
City |
Pittsburgh |
State/province |
PA |
ZIP/Postal code |
15261 |
Country |
USA |
|
|
Platforms (1) |
GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
|
Samples (5)
|
|
Relations |
BioProject |
PRJNA1093086 |